- About
- Events
- Resource Center
Archives
Test Webinar
About This Event
Test Webinar
Background
In patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) kidney size is a strong predictor of disease progression before eGFR begins to decline1. Identifying a total kidney volume (TKV) greater than expected for your patient’s age can provide an early and reliable marker for rapid disease progression which is an important step in management to delay further kidney damage1,2.Did You Know?
- A one-time kidney size measurement can assess the rate of progression of ADPKD and predict the future decline of kidney function3.
- For the first time on NephU we are bringing together a Nephrologist and Radiologist to discuss breaking down barriers encountered with TKV orders.
- Review the strengths and limitations of different imaging modalities Nephrologists can order to obtain a TKV.
- Review different methods Radiologists have available to calculate TKV.
- Discuss methods to break down communication barriers between the Nephrologist and Radiologist.
- Grantham J, et al. (2011). Nat Rev Nephrol. 7(10):556-566.
- Chapman A, et al. (2012). Clin J Am Soc Nephrol. 7(3):479-486.
- Yu A, et al. (2019). Kidney Int. 95(5):1253-1261.
Featuring
Neera Dahl, MD, PhD
Professor of Medicine (Nephrology), Medical Director of Nephrology and Director of the Nephrology Clinical Trials ProgramYale School of Medicine*
Neera Dahl, MD, PhD is currently a clinician-educator and a Professor of Medicine at Yale University, School of Medicine, Section of Nephrology. She received her MD and PhD from Tufts University School of Medicine and completed her residency and fellowship at the Beth Israel Deaconess Medical Center, in Boston, MA. She has been instrumental in developing the Yale Inherited Kidney Disease Clinical Program and is the principal investigator for several ongoing clinical trials in ADPKD. She maintains an active ADPKD registry and is involved in research exploring the role of inflammation and fibrosis in the progression of ADPKD. She is also the director of the Yale Nephrology Clinical Trials Program and a member of the Scientific Advisory Board for the Polycystic Kidney Disease Foundation.
Jill A. Green, PhD
Nephrology Medical Science DirectorOtsuka Pharmaceutical Development & Commercialization, Inc.*
Jill A Green, PhD, is a Medical Science Director in the nephrology division at Otsuka Pharmaceutical Development & Commercialization, Inc. Dr Green received her PhD in biomedical sciences, with a specialization in biochemical and molecular basis of disease. She went on to hold a research scientist role at The James Comprehensive Cancer Center at The Ohio State University, specializing in oncology pre-clinical research before taking a position as a Regulatory Compliance Officer where she managed thoracic oncology clinical trials at The James Cancer Hospital.
Dr Green has been a proud member of the PKD Foundation – Columbus, Ohio chapter for over 12 years where she has been active in fundraising and advocacy efforts.*Dr Dahl is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Green is an employee of OPDC.
If you would like to register for the 1:30 pm to 2:30 pm EDT broadcast, please click below:
Registration
Related Events
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - Events
